245 related articles for article (PubMed ID: 10344357)
1. Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure.
Aucella F; Vigilante M; Scalzulli P; Musto P; Prencipe M; Valente GL; Carotenuto M; Stallone C
Nephrol Dial Transplant; 1999 May; 14(5):1171-5. PubMed ID: 10344357
[TBL] [Abstract][Full Text] [Related]
2. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients.
Aucella F; Vigilante M; Scalzulli P; Musto P; Crisetti A; Modoni S; Carotenuto M; Stallone C
Nephrol Dial Transplant; 1998 May; 13(5):1194-9. PubMed ID: 9623553
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo.
Aucella F; Scalzulli RP; Gatta G; Vigilante M; Carella AM; Stallone C
Nephron Clin Pract; 2003; 95(4):c121-7. PubMed ID: 14694273
[TBL] [Abstract][Full Text] [Related]
4. [Calcitriol increases burst forming unit-erythroid (BFU-E) in vitro proliferation in chronic uremia. Synergic effect with DNA recombinant erythropoietin (rHu-Epo)].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
Minerva Urol Nefrol; 2001 Mar; 53(1):1-5. PubMed ID: 11346713
[TBL] [Abstract][Full Text] [Related]
5. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
[TBL] [Abstract][Full Text] [Related]
6. Circulating burst-forming-unit erythroid and the responsiveness to recombinant human erythropoietin in patients on regular hemodialytic treatment.
Brunati C; Cappellini MD; De Feo T; Stefanoni I; Civati G; Ballerini L; Fiorelli G; Minetti L
Nephron; 1992; 62(2):150-4. PubMed ID: 1436306
[TBL] [Abstract][Full Text] [Related]
7. Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin.
Brunati C; Cappellini MD; De Feo T; Guastoni C; Ballerini L; Busnach G; Civati G; Fiorelli G; Minetti L
Am J Nephrol; 1992; 12(1-2):9-13. PubMed ID: 1415372
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
[TBL] [Abstract][Full Text] [Related]
9. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
[TBL] [Abstract][Full Text] [Related]
10. Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common.
Roger SD; Stewart JH; Harris DC
Nephron; 1991; 58(1):33-6. PubMed ID: 1857480
[TBL] [Abstract][Full Text] [Related]
11. Treatment of erythropoietin-resistant anaemia with desferrioxamine in patients on haemofiltration.
Goch J; Birgegård G; Danielson BG; Wikström B
Eur J Haematol; 1995 Aug; 55(2):73-7. PubMed ID: 7628592
[TBL] [Abstract][Full Text] [Related]
12. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.
Howarth JE; Waters HM; Shanks D; Hyde K; Yin JA; Geary CG; Anastassiades E; Howarth D; Gokal R
J Clin Pathol; 1993 Jan; 46(1):41-4. PubMed ID: 8432886
[TBL] [Abstract][Full Text] [Related]
13. Burst-promoting activity in the serum of patients with chronic renal failure undergoing long-term hemodialysis.
Randall G; Meyer J; Swanepoel C; Jacobs P
Stem Cells; 1993 Sep; 11(5):428-34. PubMed ID: 8241954
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness to recombinant erythropoietin therapy in end-stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors.
Corazza F; Bergmann P; Dratwa M; Guns M; Fondu P
Nephrol Dial Transplant; 1992; 7(4):311-7. PubMed ID: 1317521
[TBL] [Abstract][Full Text] [Related]
19. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
20. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
